Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA24493 in Friedreich's ataxia: randomized, double-blind, placebo-controlled phase 2 trial
2008-003662-25Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing Lu AA24493 with Placebo (2 arms). Primary endpoint: Safety and tolerability of Lu AA24493 over 2 weeks. Started Aug 2009; status: completed.
02
Drugs
carbamoylated erythropoietin
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2008-003662-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003662-25.